Transcriptional regulation of the major zinc uptake protein hZip1 in prostate cancer cells.

PubWeight™: 0.95‹?› | Rank: Top 15%

🔗 View Article (PMC 2741159)

Published in Gene on November 05, 2008

Authors

Peter Makhov1, Konstantin Golovine, Robert G Uzzo, Torsten Wuestefeld, Benjamin J Scoll, Vladimir M Kolenko

Author Affiliations

1: Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA. petr.makhov@fccc.edu

Articles cited by this

Transcriptional regulation by the phosphorylation-dependent factor CREB. Nat Rev Mol Cell Biol (2001) 10.69

The RNA polymerase II core promoter. Annu Rev Biochem (2003) 9.37

Mammalian RNA polymerase II core promoters: insights from genome-wide studies. Nat Rev Genet (2007) 5.75

Cloning of GT box-binding proteins: a novel Sp1 multigene family regulating T-cell receptor gene expression. Mol Cell Biol (1992) 3.10

Prevalence of the initiator over the TATA box in human and yeast genes and identification of DNA motifs enriched in human TATA-less core promoters. Gene (2006) 2.31

hZIP1 zinc uptake transporter down regulation and zinc depletion in prostate cancer. Mol Cancer (2005) 2.21

Functional analysis of GC element binding and transcription in the hamster dihydrofolate reductase gene promoter. Nucleic Acids Res (1989) 2.03

Evidence for a zinc uptake transporter in human prostate cancer cells which is regulated by prolactin and testosterone. J Biol Chem (1999) 1.86

Human ZIP1 is a major zinc uptake transporter for the accumulation of zinc in prostate cells. J Inorg Biochem (2003) 1.66

Distinct activation domains within cAMP response element-binding protein (CREB) mediate basal and cAMP-stimulated transcription. J Biol Chem (1993) 1.47

Structure, function, and regulation of a subfamily of mouse zinc transporter genes. J Biol Chem (2003) 1.44

Prostate cancer in African American men is associated with downregulation of zinc transporters. Appl Immunohistochem Mol Morphol (2003) 1.37

POZ domain transcription factor, FBI-1, represses transcription of ADH5/FDH by interacting with the zinc finger and interfering with DNA binding activity of Sp1. J Biol Chem (2002) 1.27

Zinc supplementation of young men alters metallothionein, zinc transporter, and cytokine gene expression in leukocyte populations. Proc Natl Acad Sci U S A (2006) 1.21

IL-10 regulation by HIV-Tat in primary human monocytic cells: involvement of calmodulin/calmodulin-dependent protein kinase-activated p38 MAPK and Sp-1 and CREB-1 transcription factors. J Immunol (2007) 1.15

The CREB constitutive activation domain interacts with TATA-binding protein-associated factor 110 (TAF110) through specific hydrophobic residues in one of the three subdomains required for both activation and TAF110 binding. J Biol Chem (1999) 1.14

Regulation of metallothionein and zinc transporter expression in human prostate cancer cells and tissues. Cancer Lett (2003) 1.13

Transcriptional activity of Sp1 is regulated by molecular interactions between the zinc finger DNA binding domain and the inhibitory domain with corepressors, and this interaction is modulated by MEK. J Biol Chem (2005) 1.07

Regulation of the human SOX9 promoter by Sp1 and CREB. Exp Cell Res (2007) 1.07

Lack of an initiator element is responsible for multiple transcriptional initiation sites of the TATA-less mouse thymidylate synthase promoter. Mol Cell Biol (1993) 1.05

Retracted Ets-1 positively regulates Fas ligand transcription via cooperative interactions with Sp1. J Biol Chem (2002) 0.98

Sp1 and Sp3 regulate basal transcription of the human APOBEC3G gene. Nucleic Acids Res (2007) 0.97

Transcriptional control of human T-BET expression: the role of Sp1. Eur J Immunol (2007) 0.96

Vitamin E succinate inhibits NF-kappaB and prevents the development of a metastatic phenotype in prostate cancer cells: implications for chemoprevention. Prostate (2007) 0.96

Molecular basis of neuroendocrine cell type-specific expression of the chromogranin B gene: Crucial role of the transcription factors CREB, AP-2, Egr-1 and Sp1. J Neurochem (2006) 0.92

The lung enriched transcription factor TTF-1 and the ubiquitously expressed proteins Sp1 and Sp3 interact with elements located in the minimal promoter of the rat Clara cell secretory protein gene. Biochem J (1996) 0.89

Cloning and characterization of the BRD7 gene promoter. DNA Cell Biol (2006) 0.87

Sp1 is required for transcriptional activation of the fibroblast growth factor receptor 1 gene in neonatal cardiomyocytes. Gene (2007) 0.81

Articles by these authors

Guideline for management of the clinical T1 renal mass. J Urol (2009) 8.26

The R.E.N.A.L. nephrometry score: a comprehensive standardized system for quantitating renal tumor size, location and depth. J Urol (2009) 6.71

Senescence surveillance of pre-malignant hepatocytes limits liver cancer development. Nature (2011) 6.14

Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer. J Clin Oncol (2013) 4.78

The natural history of observed enhancing renal masses: meta-analysis and review of the world literature. J Urol (2006) 3.88

Excise, ablate or observe: the small renal mass dilemma--a meta-analysis and review. J Urol (2008) 3.46

Evaluating overall survival and competing risks of death in patients with localized renal cell carcinoma using a comprehensive nomogram. J Clin Oncol (2009) 3.38

A differentiation checkpoint limits hematopoietic stem cell self-renewal in response to DNA damage. Cell (2012) 3.21

Trends in radical prostatectomy: centralization, robotics, and access to urologic cancer care. Cancer (2011) 3.13

Positron emission tomography/computed tomography identification of clear cell renal cell carcinoma: results from the REDECT trial. J Clin Oncol (2012) 3.03

A complex secretory program orchestrated by the inflammasome controls paracrine senescence. Nat Cell Biol (2013) 2.98

Cutaneous metastases from genitourinary malignancies. Urology (2004) 2.97

Objective measures of renal mass anatomic complexity predict rates of major complications following partial nephrectomy. Eur Urol (2011) 2.87

Cryoablation or radiofrequency ablation of the small renal mass : a meta-analysis. Cancer (2008) 2.75

Comparison of cold and warm ischemia during partial nephrectomy in 660 solitary kidneys reveals predominant role of nonmodifiable factors in determining ultimate renal function. J Urol (2010) 2.53

Academic ranking score: a publication-based reproducible metric of thought leadership in urology. Eur Urol (2011) 2.51

Anatomic features of enhancing renal masses predict malignant and high-grade pathology: a preoperative nomogram using the RENAL Nephrometry score. Eur Urol (2011) 2.22

Prevalence of baseline chronic kidney disease in patients presenting with solid renal tumors. Urology (2011) 2.20

Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. Int J Radiat Oncol Biol Phys (2005) 2.08

Promoter hypermethylation profile of kidney cancer. Clin Cancer Res (2004) 2.02

Small renal masses progressing to metastases under active surveillance: a systematic review and pooled analysis. Cancer (2011) 1.98

The Phoenix definition of biochemical failure predicts for overall survival in patients with prostate cancer. Cancer (2008) 1.98

Rationale for percutaneous biopsy and histologic characterisation of renal tumours. Eur Urol (2012) 1.95

Urinary cytology has a poor performance for predicting invasive or high-grade upper-tract urothelial carcinoma. BJU Int (2011) 1.78

Lymphopenia is an independent predictor of inferior outcome in clear cell renal carcinoma. J Urol (2012) 1.78

Baseline renal function status limits patient eligibility to receive perioperative chemotherapy for invasive bladder cancer and is minimally affected by radical cystectomy. Urology (2010) 1.77

The expanding role of partial nephrectomy: a critical analysis of indications, results, and complications. Eur Urol (2009) 1.70

Delayed intervention of sporadic renal masses undergoing active surveillance. Cancer (2008) 1.64

Trends in regionalization of adrenalectomy to higher volume surgical centers. J Urol (2012) 1.64

Natural history, growth kinetics, and outcomes of untreated clinically localized renal tumors under active surveillance. Cancer (2009) 1.60

Enhancing renal masses with zero net growth during active surveillance. J Urol (2007) 1.59

Role of prostate dose escalation in patients with greater than 15% risk of pelvic lymph node involvement. Int J Radiat Oncol Biol Phys (2005) 1.57

Assessing performance trends in laparoscopic nephrectomy and nephron-sparing surgery for localized renal tumors. Urology (2012) 1.54

Identification of novel target genes by an epigenetic reactivation screen of renal cancer. Cancer Res (2006) 1.49

Clinical characteristics associated with treatment type for localized renal tumors: implications for practice pattern assessment. Urology (2013) 1.49

α-1-antitrypsin inhibits acute liver failure in mice. Hepatology (2014) 1.49

Decision-making strategies for patients with localized prostate cancer. Semin Urol Oncol (2002) 1.48

Nephron-sparing management vs radical nephroureterectomy for low- or moderate-grade, low-stage upper tract urothelial carcinoma. BJU Int (2014) 1.47

Utility of the R.E.N.A.L. nephrometry scoring system in objectifying treatment decision-making of the enhancing renal mass. Urology (2011) 1.46

Robot-assisted partial nephrectomy: a large single-institutional experience. Urology (2010) 1.45

Role of tumor location in selecting patients for percutaneous versus surgical cryoablation of renal masses. Can J Urol (2012) 1.45

Preoperative hydronephrosis, ureteroscopic biopsy grade and urinary cytology can improve prediction of advanced upper tract urothelial carcinoma. J Urol (2010) 1.44

Comparison of prostate cancer diagnosis in patients receiving unrelated urological and non-urological cancer care. BJU Int (2013) 1.41

Why Summary Comorbidity Measures Such As the Charlson Comorbidity Index and Elixhauser Score Work. Med Care (2015) 1.41

Enhancing renal tumors in patients with prior normal abdominal imaging: further insight into the natural history of renal cell carcinoma. J Urol (2012) 1.40

The need for androgen deprivation therapy in patients with intermediate-risk prostate cancer treated with dose-escalated external beam radiation therapy. Can J Urol (2017) 1.39

How Hugh Hampton Young's treatment of President Woodrow Wilson's urinary retention and urosepsis affected the resolution of World War I. J Urol (2011) 1.38

The relationship of increasing radiotherapy dose to reduced distant metastases and mortality in men with prostate cancer. Cancer (2004) 1.38

Histopathological characteristics of localized renal cell carcinoma correlate with tumor size: a SEER analysis. J Urol (2008) 1.37

Race, genetic West African ancestry, and prostate cancer prediction by prostate-specific antigen in prospectively screened high-risk men. Cancer Prev Res (Phila) (2009) 1.36

Diverse effects of zinc on NF-kappaB and AP-1 transcription factors: implications for prostate cancer progression. Carcinogenesis (2006) 1.33

Clinicopathological outcomes after radical cystectomy for clinical T2 urothelial carcinoma: further evidence to support the use of neoadjuvant chemotherapy. BJU Int (2011) 1.31

A critical role for notch signaling in the formation of cholangiocellular carcinomas. Cancer Cell (2013) 1.30

Prostate cancer risk assessment program: a 10-year update of cancer detection. J Urol (2007) 1.28

Zinc inhibits nuclear factor-kappa B activation and sensitizes prostate cancer cells to cytotoxic agents. Clin Cancer Res (2002) 1.28

Prostate cancer radiotherapy dose response: an update of the fox chase experience. J Urol (2004) 1.26

Residual and recurrent disease following renal energy ablative therapy: a multi-institutional study. J Urol (2006) 1.23

Detection of bladder cancer in urine by a tumor suppressor gene hypermethylation panel. Clin Cancer Res (2004) 1.22

Contemporary management of small renal masses. Eur Urol (2011) 1.19

Timing of biochemical failure and distant metastatic disease for low-, intermediate-, and high-risk prostate cancer after radiotherapy. Cancer (2007) 1.18

A review of contemporary data on surgically resected renal masses--benign or malignant? Urology (2013) 1.15

Promoter hypermethylation of tumor suppressor genes in urine from kidney cancer patients. Cancer Res (2003) 1.13

Overexpression of the zinc uptake transporter hZIP1 inhibits nuclear factor-kappaB and reduces the malignant potential of prostate cancer cells in vitro and in vivo. Clin Cancer Res (2008) 1.12

Predicting growth of solid renal masses under active surveillance. Urol Oncol (2008) 1.11

Treatment of patients with metastatic renal cell cancer: a RAND Appropriateness Panel. Cancer (2006) 1.10

Modulation of Akt/mTOR signaling overcomes sunitinib resistance in renal and prostate cancer cells. Mol Cancer Ther (2012) 1.09

Radiation therapy dose escalation for prostate cancer: a rationale for IMRT. World J Urol (2003) 1.06

PD-1 expression on peripheral blood cells increases with stage in renal cell carcinoma patients and is rapidly reduced after surgical tumor resection. Cancer Immunol Res (2013) 1.06

Optimal management of localized renal cell carcinoma: surgery, ablation, or active surveillance. J Natl Compr Canc Netw (2009) 1.05

Age, tumor size and relative survival of patients with localized renal cell carcinoma: a surveillance, epidemiology and end results analysis. J Urol (2008) 1.05

Tumor size predicts synchronous metastatic renal cell carcinoma: implications for surveillance of small renal masses. J Urol (2007) 1.05

Use of systemic therapy and factors affecting survival for patients undergoing cytoreductive nephrectomy. BJU Int (2009) 1.05

Incidence and management of penetrating renal trauma in patients with multiorgan injury: extended experience at an inner city trauma center. J Urol (2004) 1.04

Serum amino acid levels as a biomarker for renal cell carcinoma. J Urol (2011) 1.02

Low rates of adjuvant radiation in patients with nonmetastatic prostate cancer with high-risk pathologic features. Cancer (2014) 1.02

Radiation dose and late failures in prostate cancer. Int J Radiat Oncol Biol Phys (2006) 1.01

Competing risks of death in patients with localized renal cell carcinoma: a comorbidity based model. J Urol (2012) 1.01

Perioperative outcomes of robotic and open partial nephrectomy for moderately and highly complex renal lesions. J Urol (2012) 1.01

Long-term androgen deprivation increases Grade 2 and higher late morbidity in prostate cancer patients treated with three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys (2005) 1.00

Piperlongumine induces rapid depletion of the androgen receptor in human prostate cancer cells. Prostate (2012) 1.00

Evaluation and management of the renal mass. Med Clin North Am (2011) 0.99

Piperlongumine inhibits NF-κB activity and attenuates aggressive growth characteristics of prostate cancer cells. Prostate (2013) 0.99

Does a delay in external beam radiation therapy after tissue diagnosis affect outcome for men with prostate carcinoma? Cancer (2005) 0.97

Active surveillance: a potential strategy for select patients with small renal masses. Future Oncol (2011) 0.97

Defining biochemical failure after radiotherapy with and without androgen deprivation for prostate cancer. Int J Radiat Oncol Biol Phys (2005) 0.96

Does partial nephrectomy result in a durable overall survival benefit in the Medicare population? J Urol (2012) 0.96

Renal masses herniating into the hilum: technical considerations of the "ball-valve phenomenon" during nephron-sparing surgery. Urology (2009) 0.96

Vitamin E succinate inhibits NF-kappaB and prevents the development of a metastatic phenotype in prostate cancer cells: implications for chemoprevention. Prostate (2007) 0.96

Elevated expression of stromal palladin predicts poor clinical outcome in renal cell carcinoma. PLoS One (2011) 0.95

Methylseleninic acid sensitizes prostate cancer cells to TRAIL-mediated apoptosis. Oncogene (2005) 0.95